This database contains 163 studies, archived under the term: "Other"
Click here to filter this large number of results.
Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer’s disease
Li, Wei,
Zhang, Jie-Wen,
Lu, Fen,
Ma, Ming-Ming,
Wang, Jiang-qiao,
Suo, Ai-Qin,
Bai, Ying-ying,
Liu, Hui-qin
Objective: To explore the effects of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor γ-stimulating activity, on the levels of Aβ1-42, interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and cognition in elderly hypertensive patients with Alzheimer’s disease (AD).; Methods: A total of 48 patients with probable AD and essential hypertension were randomly […]
Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens
Wroolie, Tonita E.,
Kenna, Heather A.,
Williams, Katherine E.,
Powers, Bevin N.,
Holcomb, Megan,
Khaylis, Anna,
Rasgon, Natalie L.
Objective: Much controversy exists and many questions remain unanswered about the effects of hormone therapy (HT) on cognition in postmenopausal women. There is growing evidence suggesting that HT compounds containing conjugated equine estrogen (CEE) have negative effects on cognition whereas 17β-estradiol (17β-E) either has positive or neutral effects. The present study sought to further examine […]
The effects of ramipril in individuals at risk for Alzheimer’s disease: results of a pilot clinical trial
Wharton, Whitney,
Stein, James H.,
Korcarz, Claudia,
Sachs, Jane,
Olson, Sandra R.,
Zetterberg, Henrik,
Dowling, Maritza,
Ye, Shuyun,
Gleason, Carey E.,
Underbakke, Gail,
Jacobson, Laura E.,
Johnson, Sterling C.,
Sager, Mark A.,
Asthana, Sanjay,
Carlsson, Cynthia M.
Research shows that certain antihypertensives taken during midlife confer Alzheimer’s disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-β (Aβ) levels and ACE activity, arterial function, and cognition in participants with […]
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
Uenaka, Kazunori,
Nakano, Masako,
Willis, Brian A.,
Friedrich, Stuart,
Ferguson-Sells, Lisa,
Dean, Robert A.,
Ieiri, Ichiro,
Siemers, Eric R.
Objectives: Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.; Methods: Japanese and white patients with mild to moderate AD […]
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
Sinn, Natalie,
Milte, Catherine M.,
Street, Steven J.,
Buckley, Jonathan D.,
Coates, Alison M.,
Petkov, John,
Howe, Peter R.C.
Depressive symptoms may increase the risk of progressing from mild cognitive impairment (MCI) to dementia. Consumption of n-3 PUFA may alleviate both cognitive decline and depression. The aim of the present study was to investigate the benefits of supplementing a diet with n-3 PUFA, DHA and EPA, for depressive symptoms, quality of life (QOL) and […]
Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer’s disease
Sanchez-Ramos, Juan,
Cimino, Cynthia,
Avila, Ross,
Rowe, Amanda,
Chen, Ren,
Whelan, Glenn,
Lin, Xiaoyang,
Cao, Chuanhai,
Ashok, Raj
Human granulocyte colony-stimulating-factor (G-CSF) is widely used for treatment of neutropenia and to mobilize stem/progenitor cells for bone marrow transplantation. In studies of thousands of healthy donor subjects treated with G-CSF to mobilize stem/progenitor cells, the side-effect profile has been reported to be mild and reversible. In pre-clinical studies, G-CSF was reported to improve spatial […]
The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study
Padala, Kalpana P.,
Padala, Prasad R.,
McNeilly, Dennis P.,
Geske, Jenenne A.,
Sullivan, Dennis H.,
Potter, Jane F.
Background: Statins are well-known for their cardiovascular benefits. However, the cognitive effects of statins are not well understood. We hypothesized that individuals with preexisting dementia would be more vulnerable to statin-related cognitive effects.; Objective: The aim of this study was to evaluate the impact on cognition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) discontinuation and rechallenge […]
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, Susanne,
Deptula, Dennis,
Thurfjell, Lennart,
Barkhof, Frederik,
Bohrmann, Bernd,
Brooks, David J.,
Klunk, William E.,
Ashford, Elizabeth,
Yoo, Kisook,
Xu, Zhi-Xin,
Loetscher, Hansruedi,
Santarelli, Luca
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]